Stay updated on Cabiralizumab Combo in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabiralizumab Combo in Pancreatic Cancer Clinical Trial page.

Latest updates to the Cabiralizumab Combo in Pancreatic Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe record describes a completed Phase 2 study of cabiralizumab and nivolumab, alone or with chemotherapy, for advanced pancreatic cancer. It provides the study design, eligibility criteria, locations, outcome measures, and reported record dates.SummaryDifference93%

- Check8 days agoChange DetectedThe footer shows an updated ClinicalTrials.gov site revision; the study record remains unavailable and displays a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check29 days agoChange DetectedThe footer’s site revision label changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check43 days agoChange DetectedDeleted 403 Forbidden page content and the Home link from the study record page. This indicates the page is no longer blocked and navigation is simplified, allowing access to the trial details.SummaryDifference0.5%

- Check49 days agoChange DetectedThe page now shows a 403 Forbidden response instead of the study record. This indicates the record is currently inaccessible.SummaryDifference21%

Stay in the know with updates to Cabiralizumab Combo in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabiralizumab Combo in Pancreatic Cancer Clinical Trial page.